CRISPR-Cas9 globin editing can induce megabase-scale copy-neutral losses of heterozygosity in hematopoietic cells

CRISPR-Cas9 is a promising technology for gene therapy. However, the ON-target genotoxicity of CRISPR-Cas9 nuclease due to DNA double-strand breaks has received little attention and is probably underestimated. Here we report that genome editing targeting globin genes induces megabase-scale losses of...

Descripción completa

Detalles Bibliográficos
Autores principales: Boutin, J., Rosier, J., Cappellen, D., Prat, F., Toutain, J., Pennamen, P., Bouron, J., Rooryck, C., Merlio, J. P., Lamrissi-Garcia, I., Cullot, G., Amintas, S., Guyonnet-Duperat, V., Ged, C., Blouin, J. M., Richard, E., Dabernat, S., Moreau-Gaudry, F., Bedel, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363739/
https://www.ncbi.nlm.nih.gov/pubmed/34389729
http://dx.doi.org/10.1038/s41467-021-25190-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8363739/
https://www.ncbi.nlm.nih.gov/pubmed/34389729
http://dx.doi.org/10.1038/s41467-021-25190-6

Ejemplares similares